Research programme: T cell receptors natural killer T-cells therapy - Athenex
Alternative Names: T cell receptors natural killer T-cells (TCR-NKT) therapy; TCR-modified NKT-cell therapy; TCR-NKT therapyLatest Information Update: 17 Apr 2024
At a glance
- Originator National Cancer Institute (USA)
- Developer Athenex
- Class Antineoplastics; Gene therapies; Immunotherapies; NKT cell therapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer T cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Solid tumours in USA (Parenteral)
- 07 Apr 2022 Preclinical trials in Solid tumours in USA (Parenteral) (Athenex pipeline, April 2022)
- 09 Nov 2021 T cell receptors natural killer T-cells therapy is licensed to Athenex world wide (Athenex pipeline, April 2022)